arrow
M

Matthew D. Dun

university of michigan
H指数:41
被引数:5,242

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Multigenerational exposure to per- and polyfluoroalkyl substances (PFAS) negatively impacts the reproductive health of male mice

多代暴露于全氟和多氟烷基物质(PFAS)对雄性小鼠的生殖健康产生负面影响

2026-04-200
OAAI
Preclinical efficacy of combinatorial B7-H3 CAR T cells and ONC206 against diffuse intrinsic pontine glioma

组合B7-H3 CAR T细胞与ONC206对弥漫性内生性脑桥胶质瘤的疗效研究

2026-03-011
PRE
Engineered CXCR3-A expression enhances B7-H3-targeting CAR T cell migration and efficacy against diffuse intrinsic pontine glioma

工程化CXCR3-A表达增强B7-H3靶向CAR T细胞的迁移和对弥漫性内生性脑桥胶质瘤的疗效

2025-11-110
OAAI
Leveraging the immunomodulatory effects of dordaviprone (ONC201) to induce long-term survival response in diffuse midline glioma patients and models

利用dordaviprone(ONC201)的免疫调节作用,在弥漫性中线胶质瘤患者和模型中诱导长期生存反应

2025-11-010
OAAI
ENHANCING GENOME ANALYSIS WITH WHOLE PROTEOME PROFILING FOR IMPROVED THERAPEUTIC DECISION MAKING IN DIFFUSE MIDLINE GLIOMA

通过全蛋白质组分析增强基因组分析,以改善弥漫性中线胶质瘤的治疗决策制定

2025-11-010
OAAI
DISRUPTING INTEGRIN SIGNALING IMPAIRS MIGRATION, MYC-DRIVEN PURINE BIOSYNTHESIS, AND STEMNESS IN H3K27M DIFFUSE MIDLINE GLIOMAS

阻断整合素信号传导损害H3K27M弥漫性中线胶质瘤的迁移、MYC驱动的嘌呤生物合成和干性。

2025-11-010
OAAI
Precision Targeting of PI3K/mTOR in Diffuse Midline Glioma: GCT007 as a Novel Brain-Penetrant PIK3CA Inhibitor

弥漫性中线胶质瘤中PI3K/mTOR的精确靶向:GCT007作为新型脑穿透性PIK3CA抑制剂

2025-11-010
OAAI
Exposure of mice to environmentally relevant per- and polyfluoroalkyl substances (PFAS) alters the sperm epigenome

将小鼠暴露于环境相关的全氟和多氟烷基物质(PFAS)会改变其精子的表观基因组

2025-10-280
OAAI
Hypomethylating agents induce epigenetic and transcriptional heterogeneity with implications for acute myeloid leukemia cell self-renewal

去甲基化药物诱导表观遗传和转录异质性,这对急性髓系白血病细胞的自我更新具有影响。

Leukemia
IF13.4
2025-07-170
OA
Subchronic elevation in ambient temperature drives alterations to the sperm epigenome and accelerates early embryonic development in mice
2024-11-110
OAAI
If you build it, they will come: the convergence of funding, research and collaboration in paediatric brain cancer clinical trials
2024-11-070
OA
PNOC022 REPORT: A COMBINATION THERAPY TRIAL USING AN ADAPTIVE PLATFORM DESIGN FOR PATIENTS WITH DIFFUSE MIDLINE GLIOMA AT INITIAL DIAGNOSIS, POST-RADIATION THERAPY, OR PROGRESSION
2024-06-180
OAAI